NCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
Clinical Trials
23 trialsNCT00089063 2015-04-15
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089193 2014-12-23
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
University of Virginia
Phase 2 Completed
NCT00089206 2014-12-19
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Phase 2 Completed
NCT00003274 2014-05-22
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
University of Southern California
Phase 2 Completed
NCT00003339 2014-05-22
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
University of Southern California
Phase 2 Completed
NCT00031733 2014-05-22
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
University of Southern California
Phase 2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00003568 2013-06-26
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003362 2013-06-25
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00019383 2013-06-20
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019487 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019721 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00032045 2013-06-20
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019994 2013-06-19
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020358 2013-06-19
Vaccine Therapy in Treating Patients With Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00021164 2013-06-19
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00022438 2013-06-19
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072085 2013-06-19
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079144 2013-06-19
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT00006385 2011-11-08
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed